Last Price$104.91.0%
Market Cap$154.5B
LTM Property, Plant & Equipment (PPE)
$3,744.0M
YoY Growth
+13.5%
3Y CAGR
+11.7%
5Y CAGR
+9.2%
Stock quality & Intrinsic value
7/10
67.4% overvalued
Boston Scientific Corporation Property, Plant & Equipment (PPE)
Annual
Quarterly
LTM
Crunching data... Almost there!
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Property, Plant & Equipment (PPE) | $1,011.0M | $1,726.0M | $1,735.0M | $1,728.0M | $1,728.0M | $1,697.0M | $1,670.0M | $1,564.0M | $1,546.0M | $1,507.0M | $1,490.0M | $1,630.0M | $1,696.0M | $1,782.0M | $2,415.0M | $2,541.0M | $2,686.0M | $2,831.0M | $3,298.0M | $3,294.0M |
Overvalued or undervalued?
Check the intrinsic value for BSX
and see if it's the right time to invest.
Boston Scientific Corporation (BSX) Property, Plant & Equipment (PPE) comparison analysis
General
LTM Property, Plant & Equipment (PPE)
Growth
Company name
YoY growth
3Y CAGR
5Y CAGR
Boston Scientific CorporationBSX
$3,744.0M
13.5%
11.7%
9.2%
Median Peer Set
$2,062.2M
1.1%
6.3%
8.9%
Abbott LaboratoriesABT
$10.7B
(5.5%)
6.0%
5.8%
Medtronic plcMDT
$6,593.0M
12.9%
7.9%
6.7%
Stryker CorporationSYK
$3,448.0M
7.2%
6.8%
6.1%
Koninklijke Philips N.V.PHG
$2,539.0M
(7.4%)
(3.1%)
(3.1%)
STERIS plcSTE
$2,075.6M
1.8%
6.6%
11.1%
Zimmer Biomet Holdings, Inc.ZBH
$2,048.8M
(9.5%)
3.7%
(0.3%)
Edwards Lifesciences CorporationEW
$1,780.1M
0.4%
4.7%
11.2%
DexCom, Inc.DXCM
$1,402.7M
18.4%
16.4%
29.0%
Align Technology, Inc.ALGN
$1,384.5M
(1.7%)
4.8%
15.0%
Insulet CorporationPODD
$723.1M
4.4%
10.5%
12.6%
BSX key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 6,283.0 11.7% | 7,821.0 24.5% | 8,357.0 6.9% | 8,050.0 (3.7%) | 8,188.0 1.7% | 7,806.0 (4.7%) | 7,622.0 (2.4%) | 7,249.0 (4.9%) | 7,143.0 (1.5%) | 7,380.0 3.3% | 7,477.0 1.3% | 8,386.0 12.2% | 9,048.0 7.9% | 9,823.0 8.6% | 10,735.0 9.3% | 9,913.0 (7.7%) | 11,888.0 19.9% | 12,682.0 6.7% | 14,240.0 12.3% | 16,747.0 17.6% |
| Cost of Goods Sold (COGS) | 1,386.0 | 2,207.0 | 2,342.0 | 2,469.0 | 2,576.0 | 2,599.0 | 2,659.0 | 2,502.0 | 2,314.0 | 2,321.0 | 2,243.0 | 2,503.0 | 2,661.0 | 2,883.0 | 3,181.0 | 3,510.0 | 3,760.0 | 4,003.0 | 4,345.0 | 5,257.0 |
% margin | 4,897.0 77.9% | 5,614.0 71.8% | 6,015.0 72.0% | 5,581.0 69.3% | 5,612.0 68.5% | 5,207.0 66.7% | 4,963.0 65.1% | 4,747.0 65.5% | 4,829.0 67.6% | 5,059.0 68.6% | 5,234.0 70.0% | 5,883.0 70.2% | 6,387.0 70.6% | 6,940.0 70.7% | 7,554.0 70.4% | 6,403.0 64.6% | 8,128.0 68.4% | 8,679.0 68.4% | 9,895.0 69.5% | 11,490.0 68.6% |
| Operating Expenses | 3,653.0 | 4,444.0 | 5,768.0 | 7,039.0 | 6,410.0 | 4,217.0 | 3,252.0 | 3,816.0 | 3,945.0 | 4,157.0 | 4,244.0 | 4,564.0 | 4,856.0 | 5,281.0 | 5,814.0 | 5,719.0 | 6,304.0 | 6,646.0 | 7,552.0 | 8,887.0 |
| Research & Development Expenses (R&D) | 680.0 | 1,008.0 | 1,091.0 | 1,006.0 | 1,035.0 | 939.0 | 895.0 | 886.0 | 861.0 | 817.0 | 876.0 | 920.0 | 997.0 | 1,113.0 | 1,174.0 | 1,143.0 | 1,204.0 | 1,323.0 | 1,414.0 | 1,615.0 |
| Selling, General & Administrative Expenses (SG&A) | 1,814.0 | 2,675.0 | 2,909.0 | 2,566.0 | 4,848.0 | 2,765.0 | 2,659.0 | 2,535.0 | 2,674.0 | 2,902.0 | 2,873.0 | 3,099.0 | 3,294.0 | 3,569.0 | 3,941.0 | 3,787.0 | 4,359.0 | 4,520.0 | 5,190.0 | 5,984.0 |
% margin | 968.0 15.4% | (2,949.0) (37.7%) | (14.0) (0.2%) | (1,536.0) (19.1%) | (894.0) (10.9%) | (656.0) (8.4%) | 904.0 11.9% | (3,868.0) (53.4%) | 120.0 1.7% | 299.0 4.1% | (327.0) (4.4%) | 447.0 5.3% | 1,285.0 14.2% | 1,506.0 15.3% | 1,518.0 14.1% | 1,044.0 10.5% | 2,043.0 17.2% | 1,649.0 13.0% | 2,343.0 16.5% | 2,603.0 15.5% |
| Interest Income | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 13.0 | 7.0 | 5.0 | 6.0 | 5.0 | 5.0 | 5.0 | 5.0 | 3.0 | 30.0 | 3.0 | 4.0 | 10.0 | 22.0 | 107.0 |
| Interest Expense | 0.0 | 0.0 | 570.0 | 468.0 | 407.0 | 393.0 | 281.0 | 261.0 | 324.0 | 216.0 | 284.0 | 233.0 | 229.0 | 241.0 | 473.0 | 361.0 | 341.0 | 470.0 | 265.0 | 305.0 |
| Pre-tax Income | 891.0 | (3,535.0) | (569.0) | (2,062.0) | (1,308.0) | (1,063.0) | 642.0 | (4,107.0) | (223.0) | 91.0 | (650.0) | 177.0 | 933.0 | 1,422.0 | 687.0 | (138.0) | 1,076.0 | 1,141.0 | 1,985.0 | 2,282.0 |
% effective tax rate | 263.0 29.5% | 42.0 (1.2%) | (74.0) 13.0% | 10.0 (0.5%) | (283.0) 21.6% | 2.0 (0.2%) | 201.0 31.3% | (39.0) 0.9% | (102.0) 45.7% | (176.0) (193.4%) | (411.0) 63.2% | (170.0) (96.0%) | 828.0 88.7% | (249.0) (17.5%) | (4,013.0) (584.1%) | 2.0 (1.4%) | 36.0 3.3% | 443.0 38.8% | 393.0 19.8% | 436.0 19.1% |
% margin | 628.0 10.0% | (3,577.0) (45.7%) | (495.0) (5.9%) | (2,072.0) (25.7%) | (1,025.0) (12.5%) | (1,065.0) (13.6%) | 441.0 5.8% | (4,068.0) (56.1%) | (121.0) (1.7%) | 267.0 3.6% | (239.0) (3.2%) | 347.0 4.1% | 104.0 1.1% | 1,671.0 17.0% | 4,700.0 43.8% | (140.0) (1.4%) | 1,041.0 8.8% | 698.0 5.5% | 1,593.0 11.2% | 1,853.0 11.1% |
| EPS | 0.76 | (2.81) | (0.33) | (1.38) | (0.68) | (0.70) | 0.29 | (2.89) | (0.09) | 0.20 | (0.18) | 0.26 | 0.08 | 1.21 | 3.38 | (0.10) | 0.69 | 0.45 | 1.08 | 1.26 |
| Diluted EPS | 0.75 | (2.81) | (0.33) | (1.38) | (0.68) | (0.70) | 0.29 | (2.89) | (0.09) | 0.20 | (0.18) | 0.25 | 0.07 | 1.19 | 3.33 | (0.10) | 0.69 | 0.45 | 1.07 | 1.25 |
% margin | 1,295.0 20.6% | (2,319.0) (29.7%) | 940.0 11.2% | (699.0) (8.7%) | (108.0) (1.3%) | 149.0 1.9% | 1,635.0 21.5% | (3,161.0) (43.6%) | 721.0 10.1% | 433.0 5.9% | 360.0 4.8% | 1,226.0 14.6% | 2,007.0 22.2% | 2,585.0 26.3% | 2,210.0 20.6% | 1,511.0 15.2% | 2,518.0 21.2% | 2,741.0 21.6% | 3,453.0 24.2% | 2,603.0 15.5% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Boston Scientific Corporation's Property, Plant & Equipment (PPE)?
As of today, Boston Scientific Corporation's last 12-month Property, Plant & Equipment (PPE) is $3,744.0M, based on the financial report for Dec 31, 2024 (Q4’2024).
2) What is Boston Scientific Corporation's Property, Plant & Equipment (PPE) growth rate?
Over the last year, Boston Scientific Corporation's Property, Plant & Equipment (PPE) growth was 13.5%. The average annual Property, Plant & Equipment (PPE) growth rates for Boston Scientific Corporation have been 14.5% over the past three years, 9.2% over the past five years.
3) Is Boston Scientific Corporation's Property, Plant & Equipment (PPE) growth rate Good?
Over the last year, Boston Scientific Corporation's Property, Plant & Equipment (PPE) growth was 13.5%, which is higher than industry growth of 0.1%. It indicates that Boston Scientific Corporation's Property, Plant & Equipment (PPE) growth is Bad.